One method of overcoming these barriers to achieving potent anti-tumour immunity is the use of immunotherapies which can either boost immune responses (e.g. targeting CD40 on DCs) or dampen immunosuppressive mechanisms (e.g. PD-1 or PD-L1 blockade) [3,4]. The gene discussed is CD274; the disease is neoplasm.